NASDAQ$EDIT
Editas Medicine Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Editas Medicine reported a net income for Q3 2020 and made progress in its clinical programs.
Editas Medicine reported a net income of $7.8 million for the third quarter of 2020, a significant improvement compared to the net loss of $32.9 million for the same period in 2019. The company completed dosing the first cohort with EDIT-101 in the BRILLIANCE trial and remains on track to file the IND for EDIT-301 for sickle cell disease by the end of 2020.
- Completed dosing of the first cohort in the BRILLIANCE trial for EDIT-101.
- Regained full operating control of ocular programs through a new agreement with AbbVie.
- Advanced EDIT-301 for sickle cell disease with IND filing on track for the end of 2020.
- Made progress in the development of EDIT-201 for solid tumors, with preclinical data to be presented at upcoming conferences.
Headline financials
Revenue & EPS history
Editas · Revenue · Quarterly
$62.8M
Revenue by segment
Editas · $5.34M total across 1 segment · Q3 2023
- Collaboration & R&D$5.34M+12604.8%100.0%
Forward guidance
Editas Medicine is focused on advancing its pipeline of CRISPR-based medicines, with key milestones including the IND filing for EDIT-301 and continued development of EDIT-101 and EDIT-201.
Tailwinds
- Advancing EDIT-101 clinical trials.
- Filing IND for EDIT-301 by the end of 2020.
- Presenting preclinical data for EDIT-201 at upcoming conferences.
- Continuing to develop CRISPR-based medicines.
- Maintaining a strong cash position to fund operations into 2023.
Headwinds
- Uncertainties inherent in clinical trials.
- Potential delays in regulatory approvals.
- Dependence on third parties for manufacturing and clinical trial support.
- Risks related to intellectual property and patent interference.
- Potential impact of COVID-19 on clinical trial enrollment and operations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2020
+4.5%
Avg return
Earnings day
+4.4%
Avg return
5 days after
+2.0%
Avg return
30 days after
71%
29 / 41 earnings
Positive
+29.4%
Q2 2021
Best reaction
-11.8%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.3% | +3.7% | -0.7% | |
| Q4 2025 | +15.5% | +22.0% | +38.0% | |
| Q3 2025 | +1.4% | +5.3% | +5.3% | |
| Q1 2025 | -2.7% | -1.9% | +41.6% | |
| Q4 2024 | +16.5% | -11.4% | -41.5% | |
| Q3 2024 | +7.2% | +7.2% | -31.6% | |
| Q2 2024 | -10.0% | -16.2% | -23.3% | |
| Q1 2024 | -2.1% | +0.5% | -6.7% | |
| Q4 2023 | +13.5% | +12.0% | -16.3% | |
| Q3 2023 | +18.2% | +19.5% | +53.2% | |
| Q2 2023 | +7.6% | -2.5% | +5.0% | |
| Q1 2023 | +10.3% | +14.6% | +10.9% | |
| Q4 2022 | +2.3% | -1.5% | -18.7% | |
| Q3 2022 | -8.5% | -13.4% | -19.6% | |
| Q2 2022 | +16.2% | +16.1% | -10.0% | |
| Q1 2022 | +2.7% | -21.7% | -16.0% | |
| Q4 2021 | +17.3% | +21.4% | +30.2% | |
| Q3 2021 | +8.2% | +1.1% | -14.9% | |
| Q2 2021 | +29.4% | +37.9% | +62.1% | |
| Q1 2021 | -0.9% | -9.7% | -2.9% | |
| Q4 2020 | -11.8% | -8.1% | -18.6% | |
| Q3 2020 | +0.1% | -1.9% | +13.3% | |
| Q2 2020 | +6.8% | +5.2% | -6.2% | |
| Q1 2020 | -1.2% | +1.9% | +6.6% | |
| Q4 2019 | -6.7% | +1.1% | -11.2% | |
| Q3 2019 | +12.8% | +12.1% | +47.8% | |
| Q2 2019 | +2.4% | +3.8% | +1.1% | |
| Q1 2019 | -2.8% | -5.5% | -20.4% | |
| Q4 2018 | +12.8% | +12.8% | +16.7% | |
| Q3 2018 | +10.7% | +4.1% | +4.8% | |
| Q2 2018 | +0.5% | +3.3% | +11.6% | |
| Q1 2018 | +1.0% | +2.4% | +13.2% | |
| Q4 2017 | +9.9% | +14.6% | -14.5% | |
| Q3 2017 | -6.9% | +1.5% | +7.3% | |
| Q2 2017 | +4.6% | +22.8% | +6.5% | |
| Q1 2017 | -5.1% | -7.2% | -17.1% | |
| Q4 2016 | +4.4% | +19.2% | +0.8% | |
| Q3 2016 | +5.1% | +23.6% | +19.4% | |
| Q2 2016 | -9.3% | -15.1% | -27.4% | |
| Q1 2016 | +7.0% | — | — | |
| Q4 2015 | +5.9% | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro